Presentation is loading. Please wait.

Presentation is loading. Please wait.

Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty.

Similar presentations


Presentation on theme: "Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty."— Presentation transcript:

1 Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty Center for his helpful discussions and figures on the ICBG program

2 Program goals and accomplishments Objectives International Cooperative Biodiversity Groups Biodiversity exploration Scientific and economic development Biodiversity conservation Modeled on CBD ABS and Merck/InBIO agreement PIC, IP, and benefit sharing Implementation Competitive research grants (NIH/NSF/USDA) Five years, $300 – 600k/year direct costs Groups required academic institution and/or NFP, partner country, industrial partner The grand challenge Managing expectations Technology vs. sociology

3 State of the field Commercial Competing technologies and strategies Combinatorial chemistry HTP and UHTP screening Therapeutic targets/privileged stuctures Economic pressures Decline in new chemical entities Biodiversity as a commodity Political Uncertainty of access Uncertainty of provenance Uncertainty of benefit

4 Bioprospecting Plants Animals Structure Screening cultures Fermentation Solvent extraction Primary assays Synthetic compounds Biocatalysis Strain improvement Chemical isolation Dereplication Biocatalysis Secondary assays Safety Assessment Clinical Trials Patent Scale-up Medicinal chemistry Pharmacology New product Toxicology Microbial

5 Reality check # 1 David J. Newman, NCI/NIH, 2005 Unpublished

6 Reality check # 2 Baltz, R., Microbe :

7 Outcomes Drug discovery 14 years $50 M (US govt) 12 groups 7 companies 21 countries 12,000 species 1500 bioactive compounds 0 drugs Other benefits >12,000+ spp collected >1300 bioactive compounds isolated >4000 people trained (350 long term) Institutional capacity built in 16 countries Informed bioprospecting policies in at least 6 countries Initiated/ strengthened biodiversity reserves in 7 countries Tested models of intellectual property rights and benefit- sharing/Established 14 Trust Funds >500 publications

8 From A. Kuo and G.M.Garrity 2002 Exploiting Microbial Diversity, In Biodiversity of Microbial Life, J.T. Staley and A-L Reysenbach, ed, John Wiley Market size Approx. $100B

9 Why me? present Professor, Microbiology & Molecular Genetics Cofounder - Genomic Standards Consortium, Editor-in-Chief of SIGS (current), Bergey’s Manual ( ) Chair, International Committee on Systematics of Prokaryotes Cofounder, NamesforLife, LLC Merck and Co., Microbial Resources Group Bioprospecting and culture acquisition agreements, culture collection Natural products dereplication Co-inventor on 22 natural product patents


Download ppt "Session 4 - Communities of practice Natural Products Drug Discovery The ICBG Program: A view from afar* Special thanks to Joshua Rosenthal of the NIH Fogarty."

Similar presentations


Ads by Google